

## **Supplementary appendix**

This appendix has been provided by the authors to give readers additional information about their work.

Supplement to: de Hoon J, et al. Phase 1, randomized, parallel-group, double-blind, placebo-controlled trial to evaluate the effects of erenumab (AMG 334) and concomitant sumatriptan on blood pressure in healthy volunteers. *Cephalalgia*.

**Supplementary Table 1.** Pharmacokinetic parameters by cohort.

	$t_{\max}$ (hr)	$C_{\max}$ (ng/ml)	$AUC_{6hr}$ (hr*ng/ml)	$AUC_{\infty}$ (hr*ng/ml)
Group A, part 1: placebo and sumatriptan ( $N = 9$ )				
Mean $\pm$ SD	NR	74.6 $\pm$ 16.6	131.0 $\pm$ 20.0	146.0 $\pm$ 30.6
Min	0.17	58.8	100.0	106.0
Median	0.27	70.7	123.0	138.0
Max	0.53	114.0	166.0	213.0
%CV	NR	22.2	15.3	21.0
Group A, part 2: placebo and sumatriptan ( $N = 10$ )				
Mean $\pm$ SD	NR	86.8 $\pm$ 11.3	136.0 $\pm$ 24.7	148.0 $\pm$ 33.0
Min	0.17	66.2	93.5	99.2
Median	0.17	91.7	129.0	139.0
Max	0.50	98.7	168.0	211.0
%CV	NR	13.1	18.2	22.3
Group B, part 1: placebo and sumatriptan ( $N = 20$ )				
Mean $\pm$ SD	NR	84.2 $\pm$ 24.0	134.0 $\pm$ 23.7	146.0 $\pm$ 26.0
Min	0.13	47.0	104.0	112.0
Median	0.17	80.6	129.0	140.0
Max	0.55	141.0	208.0	217.0
%CV	NR	28.5	17.7	17.9
Group B, part 2: erenumab and sumatriptan ( $N = 20$ )				
Mean $\pm$ SD	NR	88.0 $\pm$ 23.2	135.0 $\pm$ 22.1	149.0 $\pm$ 23.7
Min	0.17	48.7	105.0	110.0
Median	0.25	83.9	134.0	150.0
Max	0.52	147.0	199.0	205.0

%CV	NR	26.4	16.3	16.0
-----	----	------	------	------

---

AUC: area under the plasma concentration–time curve; AUC<sub>6hr</sub>: AUC from time 0 to 6 hours;

AUC<sub>∞</sub>: AUC from time 0 to infinity; C<sub>max</sub>: maximum observed plasma concentration; CV:

coefficient of variation; NR: not reported; SC: subcutaneous; t<sub>max</sub>: time to reach C<sub>max</sub>.

Actual time in hours post–second dose of sumatriptan used in the analysis.